绥美凯的效果如何
Inbec is indicated for the treatment of adults and adolescents aged 12 years and older (who weigh at least 40 kg) infected with human immunodeficiency virus (HIV).
HIV-infected patients, regardless of race, should be screened for the HLA-B5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the HLA-B5701 allele, he should not take products containing abacavir. Patients who test positive for the HLA-B5701 allele are at higher risk of developing abacavir hypersensitivity reactions. If a patient develops a hypersensitivity reaction, use of Sumax Inbec must be stopped immediately and treatment must not be started again.
Suimeikai Inbec has been recommended by many authoritative academic institutions and authoritative guidelines in Europe and the United States as the first-line treatment of choice for patients with newly diagnosed HIV infection, and has good viral suppression effects.
Due to patent protection restrictions, many drugs are prohibited from being copied in most countries around the world. However, due to the protection of India's special patent laws, Indian Emcure Pharmaceuticals can produce drugs that are almost as effective as the original drugs and have high cost performance.
How effective is Suimeike from India's Emcure Pharmaceuticals?
Trimax Inbec is based on DTG (dolutegravir) integrase inhibitor. In clinical trials, the discontinuation rate of DTG due to adverse drug reactions (ADR) or virological failure was low, which were 5.8% and 0.5% respectively. In the SINGLE trial, the 48-week primary analysis showed that the proportion of patients who achieved virological suppression was better in the dolutegravir XxXABC/3TC group than in the FTC/TDF/ETC group. It can be seen that Suimeike Inbec has obvious viral suppression effect and low incidence of side effects, making it a good choice for HIV patients.
The above is the introduction about Inbec, I hope it can help everyone. If patients have other questions about the drug (such as drug price, purchasing channels, etc.), they can consult the medical companion travel service.
Recommended related hot articles: /newsDetail/87199.html
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)